Pilgrim Partners Asia Pte Ltd Invests $57,000 in The Beauty Health Company (NASDAQ:SKIN)

Pilgrim Partners Asia Pte Ltd bought a new stake in shares of The Beauty Health Company (NASDAQ:SKIN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,000 shares of the company’s stock, valued at approximately $57,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. FMR LLC raised its holdings in Beauty Health by 0.3% in the 3rd quarter. FMR LLC now owns 18,603,037 shares of the company’s stock worth $26,788,000 after purchasing an additional 58,826 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Beauty Health by 1.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,499,652 shares of the company’s stock valued at $3,599,000 after buying an additional 27,665 shares during the period. Geode Capital Management LLC raised its stake in Beauty Health by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,787,492 shares of the company’s stock worth $2,843,000 after buying an additional 30,825 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Beauty Health by 7.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 688,365 shares of the company’s stock worth $1,094,000 after buying an additional 45,525 shares during the period. Finally, Wells Fargo & Company MN boosted its position in Beauty Health by 66.5% during the 4th quarter. Wells Fargo & Company MN now owns 193,733 shares of the company’s stock valued at $308,000 after acquiring an additional 77,399 shares in the last quarter. Hedge funds and other institutional investors own 93.26% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group lowered their target price on Beauty Health from $1.75 to $1.50 and set a “hold” rating for the company in a research note on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $2.50.

Beauty Health Price Performance

Shares of NASDAQ SKIN opened at $1.20 on Friday. The company has a debt-to-equity ratio of 9.23, a quick ratio of 5.57 and a current ratio of 6.56. The company has a 50 day simple moving average of $1.46 and a two-hundred day simple moving average of $1.54. The Beauty Health Company has a fifty-two week low of $0.91 and a fifty-two week high of $3.92. The company has a market capitalization of $150.29 million, a price-to-earnings ratio of -2.86 and a beta of 0.84.

Beauty Health (NASDAQ:SKIN) last released its earnings results on Wednesday, March 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. The business had revenue of $83.50 million for the quarter, compared to the consensus estimate of $78.02 million. Beauty Health had a negative return on equity of 44.83% and a negative net margin of 8.11%. During the same period in the previous year, the company posted ($0.07) earnings per share. Analysts expect that The Beauty Health Company will post -0.25 EPS for the current fiscal year.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.